Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | GLA | P06280 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749830 | 0.90 | KDM4E (0.49) | KDM4EHPGDALDH1A1GLAGAA | |
| SCHEMBL27796506 | 0.85 | CSNK2A1 (0.53) | KDM4EHPGDALDH1A1GAATNIK | |
| SCHEMBL301233 | 0.84 | KDM4E (0.61) | KDM4EHPGDALDH1A1GLAGAA | |
| SCHEMBL300607 | 0.80 | KDM4E (0.59) | KDM4EHPGDALDH1A1GLAGAA | |
| SCHEMBL300795 | 0.79 | KDM4E (0.59) | KDM4EHPGDALDH1A1GLAGAA | |
| SCHEMBL300971 | 0.78 | KDM4E (0.62) | KDM4EHPGDALDH1A1GLAGAA | |
| SCHEMBL300939 | 0.78 | KDM4E (0.62) | KDM4EHPGDALDH1A1GLAGAA | |
| SCHEMBL301342 | 0.77 | KDM4E (0.65) | KDM4EHPGDALDH1A1GLAGAA | |
| SCHEMBL4223540 | 0.76 | KDM4E (0.44) | KDM4EHPGDALDH1A1GLAGAA | |
| SCHEMBL4224600 | 0.75 | KDM4E (0.53) | KDM4EHPGDALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078018-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2012-03-14 | — | — | EP | claimed |
| CN-107976546-B | Inhibition of phosphorylation of TOR kinase inhibitory Activity markers PRAS40, GSK 3-beta, or P70S6K1 | 西格诺药品有限公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-110721186-A | Treatment of prostate cancer with TOR kinase inhibitors | 西格诺药品有限公司 | 2020-01-24 | — | — | CN | disclosed |
| CN-107157990-B | Treatment of cancer with TOR kinase inhibitors | 西格诺药品有限公司 | 2020-01-07 | — | — | CN | disclosed |
| EP-2909627-A2 | INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY | Signal Pharmaceuticals, LLC (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2825171-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2825170-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2825169-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2768500-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2739751-A1 | IDENTIFICATION OF GENE EXPRESSION PROFILE AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | Signal Pharmaceuticals, LLC (US) | 2014-06-11 | — | — | EP | disclosed |
| WO-2014066125-A2 | INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2013138560-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013138557-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013138553-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013059396-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013019927-A1 | IDENTIFICATION OF GENE EXPRESSION PROFILE AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-07 | — | — | WO | disclosed |
| CN-102821767-A | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARM LLC | 2012-12-12 | — | — | CN | disclosed |
| EP-2078018-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008051494-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |